Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine
DOI 10.1038/74704

Cited by (1,006)

Items 301–400 of 1,006

  1. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    Sherif Shafik Farag, Ian W. Flinn, Rama Modali, Teresa A. Lehman, Donn C. Young, John C. Byrd · 2003 · Blood
  2. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.
    Christilyn P. Graff, Karl Dane Wittrup · 2003 · PubMed
  3. Preassociation of IL-15 with IL-15Rα-IgG1-Fc Enhances Its Activity on Proliferation of NK and CD8+/CD44high T Cells and Its Antitumor Action
    Sigrid P. Dubois, Hiral J. Patel, Meili Zhang, Thomas A. Waldmann, Jürgen R. Müller · 2008 · The Journal of Immunology
  4. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
    Kazuyoshi Takeda, Noriko Yamaguchi, Hisaya Akiba, Yuko Kojima, Yoshihiro Hayakawa, Jane E. Tanner, Thomas Joseph Sayers, Naoko Seki, Ko Okumura, Hideo Yagita∥ et al. · 2004 · The Journal of Experimental Medicine
  5. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
    Holbrook E K Kohrt, Roch Houot, Matthew Jordan Goldstein, Kipp Weiskopf, Ash A. Alizadeh, Josh Brody, Antonia M. S. Müller, Russell Kent Pachynski, Debra Katherine Czerwinski, Steven E. Coutre et al. · 2010 · Blood · Retracted
  6. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
    Qing Wu, Wei Qian, Xiaoli Sun, Shaojie Jiang · 2022 · Journal of Hematology & Oncology
  7. Production, characterization, and pharmacokinetic properties of antibodies with N-linked mannose-5 glycans
    Yu, Marcella, Brown, Darren, Reed, Chae, Chung, Shan, Lutman, Jeff, Stefanich, Eric, Wong, Anne, Stephan, Jean-Philippe, Bayer, Robert · 2012 · mAbs
  8. PT-100, a Small Molecule Dipeptidyl Peptidase Inhibitor, Has Potent Antitumor Effects and Augments Antibody-Mediated Cytotoxicity via a Novel Immune Mechanism
    Sharlene Adams, Glenn T. Miller, Michael I. Jesson, Takeshi Watanabe, Barry Nelson Jones, Barbara P. Wallner · 2004 · Cancer Research
  9. Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer
    Barbara Ingold Heppner, Michael Untch, Carsten Denkert, Berit Maria Pfitzner, Bianca Lederer, Wolfgang Schmitt, Holger Eidtmann, Peter Andreas Fasching, Hans Tesch, Christine Solbach et al. · 2016 · Clinical Cancer Research
  10. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies
    Li-Chung Tsao, Jeremy Meyer Force, Zachary C. Hartman · 2021 · Cancer Research
  11. Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
    Luca Bologna, Elisa Gotti, Massimiliano Manganini, Alessandro Rambaldi, Tamara Intermesoli, Martino Introna, Josée Golay · 2011 · The Journal of Immunology
  12. Resistance to the Antibody–Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity
    Carla Ríos‐Luci, Sara García‐Alonso, Elena Dı́az-Rodrı́guez, Mercedes Nadal‐Serrano, Joaquı́n Arribas, Alberto Ocaña, Atanasio Pandiella · 2017 · Cancer Research
  13. Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages
    Shi, Yun, Fan, Xuejun, Deng, Hui, Brezski, Randall J, Rycyzyn, Michael, Jordan, Robert E, Strohl, William R, Zou, Quanming, Zhang, Ningyan, An, Zhiqiang · 2015 · The Journal of Immunology
  14. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies
    Reed J. Harris, Steven J. Shire, Charles Winter · 2004 · Drug Development Research
  15. The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity
    Joanna Bagińska, Elodie Viry, Jérôme Paggetti, Sandrine Medves, Guy Berchem, Etienne Moussay, Bassam Janji · 2013 · Frontiers in Immunology
  16. Emerging Targeted Therapies for HER2-Positive Breast Cancer
    Maria Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro, Roxana Schillaci · 2023 · Cancers
  17. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone
    Nicola Di Gaetano, Yi Xiao, Eugenio Erba, Renato Bassan, Alessandro Rambaldi, Josée Golay, Martino Introna · 2001 · British Journal of Haematology
  18. Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas
    Anna Kruschinski, Andreas Moosmann, Isabel C. Poschke, Håkan Norell, Markus Martin Chmielewski, Barbara Seliger, Rolf W. Kiessling, Thomas J. F. Blankenstein, Hinrich Abken, Jehad Charo · 2008 · Proceedings of the National Academy of Sciences
  19. Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
    Eric P. Brown, Karen G. Dowell, Austin W. Boesch, Erica Normandin, Alison E. Mahan, Thach H. Chu, Dan H. Barouch, Chris Bailey‐Kellogg, Galit Alter, Margaret E. Ackerman · 2017 · Journal of Immunological Methods
  20. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
    Branka Petričević, Johannes Laengle, Josef Singer, Monika Sachet, Judit Fazekas, Guenther G. Steger, Rupert Bartsch, Erika Jensen‐Jarolim, Michael M. Bergmann · 2013 · Journal of Translational Medicine
  21. Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
    Fabrice André, Maria Vittoria Dieci, Peter Christian Dubsky, Christos P. Sotiriou, Giuseppe Curigliano, Carsten Denkert, Sherene Loi · 2012 · Clinical Cancer Research
  22. Ligand-targeted theranostic nanomedicines against cancer
    Virginia J. Yao, Sara D’Angelo, Kimberly S. Butler, Christophe Théron, Tracey L. Smith, Serena Marchiò, Juri George Gelovani, Richard L. Sidman, Andrey S. Dobroff, C. Jeffrey Brinker et al. · 2016 · Journal of Controlled Release
  23. Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
    Alexandre Iannello, Ali Ahmad · 2005 · Cancer and Metastasis Reviews
  24. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
    Siao‐Yi Wang, Emilian V. Racila, Ronald P. Taylor, George J. Weiner · 2007 · Blood
  25. The mechanism of anti-CD20–mediated B cell depletion revealed by intravital imaging
    Fabrício Montalvão, Zacarias Garcia, Susanna Celli, Béatrice Bréart, Jacques Deguine, Nico van Rooijen, Philippe Bousso · 2013 · Journal of Clinical Investigation
  26. Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
    Babak Nami, Hamid Maadi, Zhixiang Wang · 2018 · Cancers
  27. Functional diversification of IgGs through Fc glycosylation
    Taia T. Wang, Jeffrey V. Ravetch · 2019 · Journal of Clinical Investigation
  28. T Cell Costimulus-Independent and Very Efficacious Inhibition of Tumor Growth in Mice Bearing Subcutaneous or Leukemic Human B Cell Lymphoma Xenografts by a CD19-/CD3- Bispecific Single-Chain Antibody Construct
    Dreier, Torsten, Baeuerle, Patrick A, Fichtner, Iduna, Grün, Michael, Schlereth, Bernd, Lorenczewski, Grit, Kufer, Peter, Lutterbüse, Ralf, Riethmüller, Gert, Gjorstrup, Per et al. · 2003 · The Journal of Immunology
  29. Overexpression of HER-2/neu in uterine serous papillary cancer.
    Alessandro Davide Santin, Stefania Bellone, Murat Gökden, Michela Palmieri, Donna Campbell Dunn, Jamshed Agha, Juan J. Roman, Laura Fulper Hutchins, Sergio L. Pecorelli, Timothy O’Brien et al. · 2002 · PubMed
  30. Targeting the function of the HER2 oncogene in human cancer therapeutics
    Mark M. Moasser · 2007 · Oncogene
  31. Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies
    Hui Yi Chew, Priscila Oliveira de Lima, Jazmina L. Gonzalez Cruz, Blerida Banushi, G O Echejoh, Lingbo Hu, Shannon R. Joseph, Benedict Lum, James Rae, Jake S. O’Donnell et al. · 2020 · Cell
  32. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Deepali Sachdev, Shu Lian Li, Julie S. Hartell, Yoko Fujita‐Yamaguchi, Jeffrey S. Miller, Douglas Yee · 2003 · PubMed
  33. Immunity against cancer: lessons learned from melanoma
    Alan N. Houghton, Jason S. Gold, Nathalie E. Blachère · 2001 · Current Opinion in Immunology
  34. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
    Francisco J. Hernandez‐Ilizaliturri, Venkata Jupudy, Julie R. Ostberg, Ezogelin Oflazoglu, Amy Huberman, Elizabeth A. Repasky, Myron Stefan Czuczman · 2003 · PubMed
  35. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
    Gur Pines, Wolfgang J. Köstler, Yosef Yarden · 2010 · FEBS Letters
  36. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies
    Diana Peta-gay English, Dana M. Roque, Alessandro Davide Santin · 2013 · Molecular Diagnosis & Therapy
  37. Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent HER-Targeted Therapy
    Grazia Arpino, Carolina Gutiérrez, Heidi L. Weiss, Mothaffar Fahed Rimawi, Suleiman Alfred Massarweh, Lavina D. Bharwani, Sabino De Placido, Charles Kent Osborne, Rachel Schiff · 2007 · JNCI Journal of the National Cancer Institute
  38. An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
    Nina E. Weisser, Mário Sanches, Eric Escobar-Cabrera, Jason O’Toole, Elizabeth Whalen, Peter W. Y. Chan, Grant Wickman, Libin Abraham, Kate Choi, Bryant Harbourne et al. · 2023 · Nature Communications
  39. Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
    Akito Natsume, Mika In, Hiroyuki Takamura, Tomoaki Nakagawa, Yukiko Shimizu, Kazuko Kitajima, Masako Wakitani, So Ohta, Mitsuo Satoh, Kenya Shitara et al. · 2008 · Cancer Research
  40. FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
    Kenji Tamura, Chikako Shimizu, Takashi Hojo, Sadako Akashi‐Tanaka, Takashi Kinoshita, Kan Yonemori, T. Kouno, Noriyuki Katsumata, Masashi Ando, K. Aogi et al. · 2010 · Annals of Oncology
  41. Fcγ Receptor Function and the Design of Vaccination Strategies
    Stylianos Bournazos, Jeffrey V. Ravetch · 2017 · Immunity
  42. Targeting death-inducing receptors in cancer therapy
    Kazuyoshi Takeda, John Stagg, Hideo Yagita∥, Ko Okumura, Mark John Smyth · 2007 · Oncogene
  43. Macrophage Polarization: Anti-Cancer Strategies to Target Tumor-Associated Macrophage in Breast Cancer: A<scp>NTI</scp>-C<scp>ANCER</scp>S<scp>TRATEGIES</scp><scp>TO</scp>T<scp>ARGET</scp>TAMs<scp>IN</scp>B<scp>REAST</scp>C<scp>ANCER</scp>
    Tariq, Muhammad, Zhang, Jieqiong, Liang, Guikai, Ding, Ling, He, Qiaojun, Yang, Bo · 2017 · Journal of Cellular Biochemistry
  44. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction.
    T. Tedder, J. Poe, Karen M. Haas · 2005 · Advances in Immunology
  45. Advances in antibody-based therapy in oncology
    Sacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, Puja Sapra, Lutz Jermutus, Daniel Christ · 2023 · Nature Cancer
  46. Dissecting effects of anti-cancer drugs and cancer-associated fibroblasts by on-chip reconstitution of immunocompetent tumor microenvironments
    Nguyen, Marie, De Ninno, Adele, Mencattini, Arianna, Mermet-Meillon, Fanny, Fornabaio, Giulia, Evans, Sophia S., Cossutta, Mélissande, Khira, Yasmine, Han, Weijing, Sirven, Philémon et al. · 2018 · Cell Reports
  47. Development of a simple and rapid method for producing non‐fucosylated oligomannose containing antibodies with increased effector function
    Qun Zhou, Srinivas Shankara, Andre J Roy, Huawei Qiu, Scott D. Estes, Alison J. McVie-Wylie, Kerry Culm-Merdek, Anna Park, Clark Q. Pan, Tim Edmunds · 2007 · Biotechnology and Bioengineering
  48. Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?
    Michael J. E. Marshall, Richard J Stopforth, Mark Steven Cragg · 2017 · Frontiers in Immunology
  49. Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
    Purva Bali, Michael Pranpat, Ramona F. Swaby, Warren C. Fiskus, Hirohito Yamaguchi, Maria E. Balasis, Kathy Rocha, Hong‐Gang Wang, Victoria M. Richon, Kapil N. Bhalla · 2005 · Clinical Cancer Research
  50. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities
    Michele De Palma, Douglas Hanahan · 2012 · Molecular Oncology
  51. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts
    Douglas C. Saffran, Arthur B. Raitano, René Hubert, Owen N. Witte, Robert Evan Reiter, Aya Jakobovits · 2001 · Proceedings of the National Academy of Sciences
  52. Antibody-based therapies for malaria
    Pleass, Richard J., Holder, Anthony A. · 2005 · Nature Reviews Microbiology
  53. DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases
    Christopher J. Chan, Daniel Mark Andrews, Nicole M. McLaughlin, Hideo Yagita∥, Susan Gilfillan, Marco Colonna, Mark John Smyth · 2009 · The Journal of Immunology
  54. Essential Role of TRPC6 Channels in G2/M Phase Transition and Development of Human Glioma
    Xia Ding, Zhuohao He, Kechun Zhou, Ju Cheng, Hailan Yao, Dongliang Lu, Rong Cai, Yening Jin, Bin Dong, Yinghui Xu et al. · 2010 · JNCI Journal of the National Cancer Institute
  55. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
    Robin Parihar, Julie E. Dierksheide, Yan Hu, William Edgar Carson · 2002 · Journal of Clinical Investigation
  56. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy
    Christian Philipp Pallasch, Ilya B. Leskov, Christian Joerg Braun, Daniela Vorholt, Adam C.B. Drake, Yadira M. Soto‐Feliciano, Eric Huttenlocher Bent, Janine Schwamb, Bettina Panagiota Iliopoulou, Nadine Kutsch et al. · 2014 · Cell
  57. Models for prevention and treatment of cancer: Problems vs promises
    Bharat Bhushan Aggarwal, Divya Danda, Shan R. Gupta, Prashasnika Gehlot · 2009 · Biochemical Pharmacology
  58. Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity
    Kazuhiro Masuda, Tsuguo Kubota, Etsuji Kaneko, Shigeru Iida, Masako Wakitani, Yukari Kobayashi-Natsume, Ai Kubota, Kenya Shitara, Kazuyasu Nakamura · 2007 · Molecular Immunology
  59. The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy
    Xuhui Zhou, Weiguo Hu, Xuebin Qin · 2008 · The Oncologist
  60. Humanized mouse model supports development, function, and tissue residency of human natural killer cells
    Dietmar Herndler‐Brandstetter, Liang Shan, Yi Yao, Carmen Stecher, Valerie Plajer, Melanie Lietzenmayer, Till Strowig, Marcel R. de Zoete, Noah W. Palm, Jie Chen et al. · 2017 · Proceedings of the National Academy of Sciences
  61. HER-2-targeted therapy: lessons learned and future directions.
    Rita Nahta, Francisco J. Esteva · 2003 · PubMed
  62. Synergistic Innate and Adaptive Immune Response to Combination Immunotherapy with Anti-Tumor Antigen Antibodies and Extended Serum Half-Life IL-2
    Eric F. Zhu, S. Annie Gai, Cary F. Opel, Byron H. Kwan, Rishi Surana, Martín C. Mihm, Monique J. Kauke, Kelly Dare Moynihan, Alessandro Angelini, Robert T. Williams et al. · 2015 · Cancer Cell
  63. Myeloid-derived suppressor cells in breast cancer
    Joseph Markowitz, Robert Wesolowski, Tracey L. Papenfuss, Taylor Brooks, William Edgar Carson · 2013 · Breast Cancer Research and Treatment
  64. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy
    Xin Chen, Xiaomin Song, Kang Li, Tong Zhang · 2019 · Frontiers in Immunology
  65. Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China
    Meng Zhang, Yiran Zhang, Lijuan Zhang, Qingwu Tian · 2019 · Progress in molecular biology and translational science
  66. Apoptotic-Regulatory and Complement-Protecting Protein Expression in Chronic Lymphocytic Leukemia: Relationship to In Vivo Rituximab Resistance
    Rajat Bannerji, Shinichi Kitada, Ian W. Flinn, Michael Pearson, Donn C. Young, John C. Reed, John C. Byrd · 2003 · Journal of Clinical Oncology
  67. Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy
    Liat Binyamin, R. Katherine Alpaugh, Tracey L. Hughes, Charles T. Lutz, Kerry S. Campbell, Louis M. Weiner · 2008 · The Journal of Immunology
  68. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies
    Mitsuo Satoh, Shigeru Iida, Kenya Shitara · 2006 · Expert Opinion on Biological Therapy
  69. Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model
    Francisco J. Hernandez‐Ilizaliturri, Nishitha M Reddy, Beata Holkova, Edris Ottman, Myron Stefan Czuczman · 2005 · Clinical Cancer Research
  70. Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA
    Katsuhiro Mori, Reiko Kuni‐Kamochi, Naoko Yamane‐Ohnuki, Masako Wakitani, Kazuya Yamano, Harue Imai, Yutaka Kanda, Rinpei Niwa, Shigeru Iida, Kazuhisa Uchida et al. · 2004 · Biotechnology and Bioengineering
  71. Functional Characteristics of the High Affinity IgG Receptor, FcγRI
    Cees E. van der Poel, Robbert M. Spaapen, Jan G. J. van de Winkel, Jeanette H.W. Leusen · 2011 · The Journal of Immunology
  72. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients
    Vincenzo Graziano, Antonino Grassadonia, Laura Iezzi, Patrizia Vici, Laura Pizzuti, Maddalena Barba, Alberto Quinzii, Annarita Camplese, Pietro Di Marino, Marta Peri et al. · 2019 · The Breast
  73. Reovirus Oncolysis of Human Breast Cancer
    Kara L. Norman, Matthew C. Coffey, Kensuke Hirasawa, Douglas J. Demetrick, Sandra G. Nishikawa, Lisa Difrancesco, James E. Strong, Patrick W.K. Lee · 2002 · Human Gene Therapy
  74. Cetuximab induce antibody‐dependent cellular cytotoxicity against EGFR‐expressing esophageal squamous cell carcinoma
    Yoshihiko Kawaguchi, Koji Kono, Kousaku Mimura, Hidemitsu Sugai, Hidenori Akaike, Hideki Fujii · 2006 · International Journal of Cancer
  75. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density
    Niwa, Rinpei, Sakurada, Mikiko, Kobayashi, Yukari, Uehara, Aya, Matsushima, Kouji, Ueda, Ryuzo, Nakamura, Kazuyasu, Shitara, Kenya · 2005 · Clinical Cancer Research
  76. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
    Falk Nimmerjahn, Sina Gordan, Anja Lux · 2015 · Trends in Immunology
  77. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
    Tsipi Ben-Kasus, Bilha Schechter, Sara Lavi, Yosef Yarden, Michael Sela · 2009 · Proceedings of the National Academy of Sciences
  78. Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
    Ann L. White, H.T. Claude Chan, Ruth R. French, Jane E. Willoughby, Christopher Ian Mockridge, Ali Roghanian, Christine A. Penfold, Steven G. Booth, Ali Dodhy, Marta Ewa Polak et al. · 2014 · Cancer Cell
  79. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
    Ivar Bleumer, Alexander K. Knuth, Egbert Oosterwijk, Rainer W. Hofmann, Zoltán Varga, C Lamers, Wim H.J. Kruit, S.  W.  Melchior, Carola Mala, S Ullrich et al. · 2004 · British Journal of Cancer
  80. Recognition and Regulation of T Cells by NK Cells
    Katharina Pallmer, Annette Oxenius · 2016 · Frontiers in Immunology
  81. Mechanisms of action of therapeutic antibodies for cancer
    Jason Mark Redman, Elizabeth Hill, Dalal S. Aldeghaither, Louis M. Weiner · 2015 · Molecular Immunology
  82. Monoclonal antibodies for the treatment of cancer
    Casey W. Shuptrine, Rishi Surana, Louis M. Weiner · 2012 · Seminars in Cancer Biology
  83. Characterization of a New Humanized Anti-CD20 Monoclonal Antibody, IMMU-106, and Its Use in Combination with the Humanized Anti-CD22 Antibody, Epratuzumab, for the Therapy of Non-Hodgkin’s Lymphoma
    Rhona Stein, Zhengxing Qu, Susan Elizabeth Chen, Adriane Rosario, Victoria Shi, Marianne K. Hayes, Ivan David Horak, Hans J. Hansen, David M. Goldenberg · 2004 · Clinical Cancer Research
  84. Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
    Mahlknecht, Georg, Maron, Ruth, Mancini, Maicol, Schechter, Bilha, Sela, Michael, Yarden, Yosef · 2013 · Proceedings of the National Academy of Sciences
  85. Camouflage and sabotage: tumor escape from the immune system
    Isabel C. Poschke, Dimitrios Mougiakakos, Rolf W. Kiessling · 2011 · Cancer Immunology Immunotherapy
  86. Optimization of Fc-mediated effector functions of monoclonal antibodies
    William R. Strohl · 2009 · Current Opinion in Biotechnology
  87. Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells
    Katja Srpan, Ashley R. Ambrose, Alexandros Karampatzakis, Mezida B. Saeed, Adam N.R. Cartwright, Karolin Guldevall, Gabriela Dos Santos Cruz De Matos, Björn Önfelt, Daniel M. Davis · 2018 · The Journal of Cell Biology
  88. Molecular predictors of response to trastuzumab and lapatinib in breast cancer
    Francisco J. Esteva, Dihua Yu, Mien‐Chie Hung, Gabriel N. Hortobágyi · 2009 · Nature Reviews Clinical Oncology
  89. Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.
    Efrat Dotan, Charu Aggarwal, Mitchell Reed Smith · 2010 · PubMed Central
  90. Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin’s Lymphoma
    William Larry Gluck, Deborah Hurst, Alan R. Yuen, Alexandra M. Levine, Mark A. Dayton, Jon P. Gockerman, Jennifer B. Lucas, Kimberly S. Denis-Mize, Barbara Tong, Dawn Navis et al. · 2004 · Clinical Cancer Research
  91. EGFR, HER2 and VEGF Pathways
    Michael F. Press, Heinz‐Josef Lenz · 2007 · Drugs
  92. Fully human therapeutic monoclonal antibodies.
    Weiner, Louis M · 2006 · Journal of Immunotherapy
  93. Targeted therapies for non-small cell lung cancer
    Wolfram C. M. Dempke, Tamás Sütö, Martin Reck · 2009 · Lung Cancer
  94. IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells
    Robin Parihar, Julie E. Dierksheide, Yan Hu, William Edgar Carson · 2002 · Journal of Clinical Investigation
  95. Targeting CD137 enhances the efficacy of cetuximab
    Kohrt, Holbrook E., Colevas, A. Dimitrios, Houot, Roch, Weiskopf, Kipp, Goldstein, Matthew J., Lund, Peder, Mueller, Antonia, Sagiv-Barfi, Idit, Marabelle, Aurelien, Lira, Ruth et al. · 2014 · Journal of Clinical Investigation · Retracted
  96. The Epidermal Growth Factor Receptor and Its Ligands in Cardiovascular Disease
    Nader M. Makki, Kristina W. Thiel, Francis J. Miller · 2013 · International Journal of Molecular Sciences
  97. Size-Dependent Segregation Controls Macrophage Phagocytosis of Antibody-Opsonized Targets
    Matthew H. Bakalar, Aaron M. Joffe, Eva M. Schmid, Sungmin Son, Marija Podolski, Daniel A. Fletcher · 2018 · Cell
  98. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
    Ricardo Lima Barros Costa, Brian J. Czerniecki · 2020 · npj Breast Cancer
  99. FUT8 Alpha-(1,6)-Fucosyltransferase in Cancer
    Kayla Bastian, Emma Scott, David J. Elliott, Jennifer Munkley · 2021 · International Journal of Molecular Sciences
  100. Monoclonal antibodies capable of discriminating the human inhibitory Fcγ‐receptor IIB (CD32B) from the activating Fcγ‐receptor IIA (CD32A): biochemical, biological and functional characterization
    Maria-Concetta Verı́, Sergey N. Gorlatov, Hua Li, Steve Burke, Syd Johnson, Jeffrey B. Stavenhagen, Kathryn E. Stein, Ezio Bonvini, Scott Koenig · 2007 · Immunology